Lucid Diagnostics Inc
NASDAQ:LUCD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Lucid Diagnostics Inc
Other Long-Term Assets
Lucid Diagnostics Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
Other Long-Term Assets
$47k
|
CAGR 3-Years
-65%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Other Long-Term Assets
$4.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
23%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Other Long-Term Assets
$1.9B
|
CAGR 3-Years
31%
|
CAGR 5-Years
41%
|
CAGR 10-Years
19%
|
|
|
Stryker Corp
NYSE:SYK
|
Other Long-Term Assets
$3.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
12%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Other Long-Term Assets
$18.4B
|
CAGR 3-Years
42%
|
CAGR 5-Years
38%
|
CAGR 10-Years
22%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Other Long-Term Assets
$1.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
16%
|
CAGR 10-Years
26%
|
|
Lucid Diagnostics Inc
Glance View
Lucid Diagnostics, Inc. develops medical testing devices. The company is headquartered in New York City, New York. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an office procedure. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next generation sequencing (NGS) deoxyribonucleic acid (DNA) assay performed on surface esophageal cells collected with EsoCheck. The firm is a subsidiary of PAVmed Inc.
See Also
What is Lucid Diagnostics Inc's Other Long-Term Assets?
Other Long-Term Assets
47k
USD
Based on the financial report for Dec 31, 2025, Lucid Diagnostics Inc's Other Long-Term Assets amounts to 47k USD.
What is Lucid Diagnostics Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
-43%
Over the last year, the Other Long-Term Assets growth was -96%. The average annual Other Long-Term Assets growth rates for Lucid Diagnostics Inc have been -65% over the past three years , -43% over the past five years .
